TLSI H.C. Wainwright raised the firm's price target on TriSalus Life Sciences to $12 from $11 and keeps a Buy rating on the shares. Following TriNav Advance clearance, the firm upped its liver procedure-volume growth assumptions from 2027 and beyond.
TLSI H.C. Wainwright raised the firm's price target on TriSalus Life Sciences to $12 from $11 and keeps a Buy rating on the shares. Following TriNav Advance clearance, the firm upped its liver procedure-volume growth assumptions from 2027 and beyond.